Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HSKA | Common Stock | Disposed to Issuer | -$2.6M | -21.7K | -100% | $120.00 | 0 | Jun 13, 2023 | Direct | F1 |
transaction | HSKA | Common Stock | Disposed to Issuer | -$1.71M | -14.3K | -100% | $120.00 | 0 | Jun 13, 2023 | by Bethany Creek | F1, F2 |
transaction | HSKA | Common Stock | Disposed to Issuer | -$857K | -7.14K | -100% | $120.00 | 0 | Jun 13, 2023 | by Lindberg Capital | F1, F3 |
David E. Sveen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, in exchange for cash consideration of $120.00 per share of common stock of the Issuer on the effective date of the merger. |
F2 | Represents shares held by Bethany Creek Partners, LP. Dr. Sveen is a general partner of and an investor in Bethany Creek Partners, LP. |
F3 | Represents shares held by Lindberg Capital Partners, LP. Dr. Sveen is a general partner of and an investor in Lindberg Capital Partners, LP. |